The AVITHRAPID consortium "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases" is part of the Horizon Europe Framework Programme and consists of 18 participants and partners from 8 countries.
Project
Description
Outcome &
Deliverables
Research
Repositories
Latest News & Events from AVITHRAPID
Halicin: A Dual-Action Molecule Against COVID-19 – New Findings from AVITHRAPID
AVITHRAPID scientists uncover how a repurposed antibiotic disrupts the core of the coronavirus replication machinery – opening new doors for broad-spectrum antiviral development. A Strategic Target: The Viral Protease 3CLpro SARS-CoV-2, the virus behind COVID-19, uses a specific enzyme, the 3C-like protease
AVITHRAPID at INF-ACT Conference
The partners of AVITHRAPID strive to disseminate project activities during key scientific events, both at local and international level. High-profile conferences are pivotal opportunities to meet academia and industries and confront with state-of-the-art research in AVITHRAPID-related topics. This INF-ACT conference, held in
AVITHRAPID project meets HERA
On 3 March 2025, the AVITHRAPID consortium met HERA during the first AVITHRAPID seminar to foster collaboration and explore new opportunities in the domain of antivirals as response against pandemic infectious diseases. During the online meeting, Prof. Bjoern Windshuegel and Prof. Vincenzo